Coeptis Therapeutics Holdings, Inc.
COEP
$15.92
-$0.04-0.25%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 501.00K | 263.60K | 62.90K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 501.00K | 263.60K | 62.90K | -- | -- |
| Cost of Revenue | 135.60K | 90.40K | 45.20K | -- | -- |
| Gross Profit | 365.50K | 173.20K | 17.70K | -- | -- |
| SG&A Expenses | 11.27M | 10.52M | 8.57M | 6.72M | 7.26M |
| Depreciation & Amortization | 1.00M | 1.00M | 1.00M | 1.00M | 1.00M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.72M | 13.15M | 11.25M | 10.05M | 11.26M |
| Operating Income | -13.22M | -12.88M | -11.19M | -10.05M | -11.26M |
| Income Before Tax | -13.67M | -12.60M | -11.30M | -10.88M | -11.62M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.67 | -12.60 | -11.30 | -10.88 | -11.62 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.38M | 1.32M | 1.52M | 1.16M | 96.30K |
| Net Income | -12.29M | -11.28M | -9.77M | -9.72M | -11.52M |
| EBIT | -13.22M | -12.88M | -11.19M | -10.05M | -11.26M |
| EBITDA | -12.08M | -11.79M | -10.14M | -9.05M | -10.26M |
| EPS Basic | -3.74 | -3.21 | -3.60 | -4.30 | -5.56 |
| Normalized Basic EPS | -2.04 | -1.79 | -1.95 | -2.43 | -3.48 |
| EPS Diluted | -3.74 | -3.21 | -3.60 | -4.30 | -5.56 |
| Normalized Diluted EPS | -2.04 | -1.79 | -1.95 | -2.43 | -3.48 |
| Average Basic Shares Outstanding | 13.60M | 48.66M | 46.81M | 45.51M | 45.16M |
| Average Diluted Shares Outstanding | 13.60M | 48.66M | 46.81M | 45.51M | 45.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |